JETEMA, Co., Ltd. (216080.KQ)
KRW 15130.0
(-2.64%)
KRW 15130.0
(-2.64%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 25.66 Billion KRW | 36.52% |
| 2022 | 17.54 Billion KRW | 47.83% |
| 2021 | 11.86 Billion KRW | -12.67% |
| 2020 | 13.58 Billion KRW | -15.52% |
| 2019 | 16.08 Billion KRW | 67.59% |
| 2018 | 9.59 Billion KRW | 46.7% |
| 2017 | 6.54 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 7.91 Billion KRW | 11.17% |
| 2024 Q1 | 7.12 Billion KRW | 1.06% |
| 2023 Q1 | 4.76 Billion KRW | -22.65% |
| 2023 Q3 | 6.25 Billion KRW | 6.15% |
| 2023 Q2 | 5.88 Billion KRW | 23.61% |
| 2023 FY | 23.94 Billion KRW | 36.52% |
| 2023 Q4 | 7.04 Billion KRW | 12.75% |
| 2022 Q2 | 4.23 Billion KRW | 26.07% |
| 2022 Q1 | 3.35 Billion KRW | 25.61% |
| 2022 Q3 | 4.71 Billion KRW | 11.36% |
| 2022 FY | 17.54 Billion KRW | 47.83% |
| 2022 Q4 | 6.15 Billion KRW | 30.7% |
| 2021 Q3 | 3.39 Billion KRW | 4.46% |
| 2021 Q4 | 2.67 Billion KRW | -21.4% |
| 2021 Q1 | 2.54 Billion KRW | -14.96% |
| 2021 FY | 11.86 Billion KRW | -12.67% |
| 2021 Q2 | 3.25 Billion KRW | 28.04% |
| 2020 Q3 | 4.08 Billion KRW | -27.26% |
| 2020 Q1 | 4.44 Billion KRW | -30.13% |
| 2020 FY | 13.58 Billion KRW | -15.52% |
| 2020 Q4 | 2.98 Billion KRW | -26.91% |
| 2020 Q2 | 5.62 Billion KRW | 26.59% |
| 2019 Q3 | 4.32 Billion KRW | 0.0% |
| 2019 FY | 16.08 Billion KRW | 67.59% |
| 2019 Q4 | 6.35 Billion KRW | 47.01% |
| 2019 Q1 | 3.97 Billion KRW | 0.0% |
| 2018 Q1 | 1.43 Billion KRW | 0.0% |
| 2018 FY | 9.59 Billion KRW | 46.7% |
| 2017 FY | 6.54 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 76.666% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -227.108% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 53.904% |
| Bioneer Corporation | 204.55 Billion KRW | 87.454% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -231.573% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 60.707% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | 20.716% |
| Helixmith Co., Ltd | 37.36 Billion KRW | 31.319% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 91.025% |
| Medy-Tox Inc. | 110.88 Billion KRW | 76.855% |
| Peptron, Inc. | 16.65 Billion KRW | -54.079% |
| Amicogen, Inc. | 52.82 Billion KRW | 51.415% |
| Genexine, Inc. | 41.62 Billion KRW | 38.349% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -58.75% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 73.976% |
| ALTEOGEN Inc. | 40.93 Billion KRW | 37.305% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 71.306% |
| SillaJen, Inc. | 5.11 Billion KRW | -402.017% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | 27.192% |
| Genomictree Inc. | 16.26 Billion KRW | -57.79% |
| MedPacto, Inc. | 26.91 Billion KRW | 4.662% |
| D&D Pharmatech | 32.16 Billion KRW | 20.206% |
| EASY BIO,Inc. | 29.67 Billion KRW | 13.506% |
| GI Innovation, Inc. | 57.59 Billion KRW | 55.438% |